RxDoctor Payments Data

Scott Sharp, MD

Interventional Cardiology · Indianapolis, INNPI 1518966712

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $26,331 of the $41,219 with a category attached, or 63.9%. Teleflex LLC accounts for 78.3% of it on its own, with 46 other manufacturers making up the rest. Reporting peaked in 2019 at $13,718 and has fallen 89.7% since, to $1,411 in 2025. Among interventional cardiology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,219in general payments, 2019–2025

Across 367 payments — averaging $112.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$32K
  • Boston Scientific$3K
  • Abiomed$637
  • Abbott$494
  • Cardiovascular Systems Inc.$349
  • AstraZeneca$333
  • plus $4K from 41 others

What the payments were for

  • Consulting fees$3,1888%
  • Speaking & faculty fees$26,33164%
  • Travel & lodging$3,5028%
  • Food & beverage$8,07820%
  • Education$1210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,219 in reported general payments places this provider in the 90th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$176,425
Medicare patients
576
Services billed
1,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban372$406,911
Repatha SureclickEvolocumab243$321,346
EntrestoSacubitril/Valsartan146$192,137
XareltoRivaroxaban123$131,328
Praluent PenAlirocumab41$58,205
FarxigaDapagliflozin Propanediol34$45,066
JardianceEmpagliflozin36$41,713
Ranolazine ErRanolazine165$20,805
BrilintaTicagrelor15$16,305
LivaloPitavastatin Calcium12$11,333
Metoprolol Succinate538$7,471
ClopidogrelClopidogrel Bisulfate554$6,405
Isosorbide Mononitrate ErIsosorbide Mononitrate451$5,712
Rosuvastatin Calcium337$5,542
Atorvastatin Calcium596$5,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$277$406,911372 claims
NovartisEntresto$332$192,137146 claims
Johnson & JohnsonXarelto$330$131,328123 claims
AstraZenecaFarxiga, Brilinta$333$61,37149 claims
Boehringer IngelheimJardiance$204$41,71336 claims
Kowa Pharmaceuticals America, Inc.Livalo$35$11,33312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →